Lilly says its experimental drug retatrutide met the primary endpoint and key secondary endpoints in a new study.

About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

The problem is that at about age 30, adults already begin losing muscle at about 3-5%  every 10 years, according to the ...

Indianapolis-based Eli Lilly just logged another big win in the metabolic medicine race, reporting that its experimental triple-agonist drug retatrutide cleared a late-stage trial in people with type ...

Eli Lilly's weight-loss drug retatrutide met the primary and key secondary endpoints in a Phase 3 trial. Participants of the trial who were taking 12 milligrams of retatrutide lost an average of 36.6 ...

Drugs like Wegovy and Zepbound have been hailed as miracle treatments. But one in 10 people are what scientists call ...

With the obesity numbers for Eli Lilly’s retatrutide already stacking up nicely, the company has rounded out its pitch for the triple agonist with top-line data on its ability to lower blood sugar ...

Lancashire's director of public health says there needs to a wider conversation about healthy eating.